• OMass Therapeutics announced an oversubscribed $310 million (£230 million) Series C financing on October 15, 2026.
• The biotechnology company develops small-molecule therapeutics in endocrinology and immunology.
• Bain Capital Life Sciences, Forbion and Novo Holdings co-led the round; existing investor Sanofi Ventures also participated.
• Proceeds will advance MC2 receptor antagonist OMS1620 through Phase 2 development for congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome.
• Funding will also support initial clinical data for an SLC15A4 inhibitor targeting lupus and other immune-related diseases.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sanofi Ventures published the original content used to generate this news brief on October 15, 2026, and is solely responsible for the information contained therein.